Targeting the PI3K/AKT/PTEN Pathway in HR+/HER2- Locally Advanced and Metastatic Breast Cancer : Episode 1
Opinion
Video
Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.
Now Viewing
EP: 1.Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer
EP: 2.First-Line Treatment Options in HR+/HER2- Locally Advanced and Metastatic Breast Cancer and Challenges with Treatment Resistance
EP: 3.Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway
EP: 4.Clinical Decision Making to Overcome Treatment Resistance in 2L HR+/HER2- Locally Advanced or Metastatic Breast Cancer
EP: 5.Targeted Therapies in HR+/HER2- Locally Advanced or Metastatic Breast Cancer: CAPItello-291
EP: 6.Other Trials of Note Investigating Targeted Therapies in Later-line HR+/HER2- Locally Advanced or Metastatic Breast Cancer
EP: 7.Adverse Event Monitoring and Management in HR+/HER2- Locally Advanced and Metastatic Breast Cancer
EP: 8.Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Related Videos
Related Content
%20(2)%201-Recovered-Recovered.jpg?fit=crop&auto=format)
